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Abstract
Background: Pre-operative anaemia is associated with mortality and red blood cell (RBC) transfusion requirement
after cardiac surgery. However, the effect on post-operative total morbidity burden (TMB) is unknown. We explored
the effect of pre-operative anaemia on post-operative TMB.
Methods: Data were drawn from the Cardiac Post-Operative Morbidity Score (C-POMS) development study
(n = 442). C-POMS describes and quantifies (0–13) TMB after cardiac surgery by noting the presence/absence of 13
morbidity domains on days 3 (D3), 5 (D5), 8 (D8) and 15 (D15). Anaemia was defined as a haemoglobin
concentration below 130 g/l for men and 120 g/l for women.
Results: Most patients were White British (86.1%) and male (79.2%) and underwent coronary artery bypass surgery
(67.4%). Participants with pre-operative anaemia (n = 137, 31.5%) were over three times more likely to receive RBC
transfusion (OR 3.08, 95%CI 1.88–5.06, p < 0.001), had greater D3 and D5 TMB (5 vs 3, p < 0.0001; 3 vs 2, p < 0.0001,
respectively) and remained in hospital 2 days longer (8 vs 6 days, p < 0.0001) than non-anaemic patients. Transfused
patients remained in hospital 5 days longer than non-transfused patients (p < 0.0001), had higher TMB on
all days (all p < 0.001) and suffered greater pulmonary, renal, GI, neurological, endocrine and ambulation
morbidities (p 0.026 to <0.001). Pre-operative anaemia and RBC transfusion were independently associated
with increased C-POMS score.
Conclusions: Pre-operative anaemia and RBC transfusion are independently associated with increased post-operative
TMB. Understanding TMB may assist in post-operative patient management to reduce morbidity. We recommend the
use of the C-POMS tool as a standard outcome tool in further studies.
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Background
Anaemia, defined as circulating haemoglobin (Hb) con-
centration level below 130 g/l for men and 120 g/l for
women (World Health Organization 2008), affects 24.8%
of the global population (World Health Organization
2008), and up to 54.4% of cardiac surgery patients (Hung
et al. 2011) are anaemic prior to surgery.
Since Hb is the circulation’s oxygen-carrying molecule,
anaemia is associated with decreased blood oxygen
content. Unless compensated for by increased blood
flow, inadequate tissue oxygen delivery (Kurtz et al.
2010) may impair organ function. Furthermore, iron is
not only essential for the synthesis of Hb’s haem moiety
but also plays an important role in oxidative metabolism
(Dunn et al. 2007). Iron deficiency may thus directly im-
pair mitochondrial oxidative metabolism and adenosine
triphosphate (ATP) synthesis through direct mitochon-
drial effects, as well as through anaemia and resulting
impairment of oxygen delivery (Davies et al. 1982). In
pre-operative anaemic patients, these deficits follow the
patient into surgery, which itself is associated with a
substantial and sustained increase in metabolic activity
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and hence in oxygen demand (Vallet and Futier 2010).
By limiting the capacity to respond to this increased
metabolic demand, pre-operative anaemia might thus be
postulated to impair post-operative recovery.
Indeed, pre-operative anaemia has been associated
with adverse outcome after cardiac surgery and has
been associated with higher mortality (Hung et al.
2011; Zindrou et al. 2002; Cladellas et al.; van Straten
et al. 2009; De Santo et al. 2009; Boening et al. 2011;
Miceli et al. 2014), longer stay on the intensive care
unit (ICU) (Hung et al. 2011; De Santo et al. 2009)
and in hospital (Cladellas et al.; De Santo et al. 2009;
Miceli et al. 2014; Kulier et al. 2007) and a higher
incidence red blood cell (RBC) transfusion (De Santo
et al. 2009; Boening et al. 2011). However, the
evidence relating to the influence of pre-operative
anaemia on post-operative morbidity is divided and
only relates to specific outcomes, for example stroke
(Cladellas et al.; Miceli et al. 2014; Fowler et al.) and
renal dysfunction (Cladellas et al.; Miceli et al. 2014;
Fowler et al.; Carrascal et al. 2010). Thus, whether
anaemia is an independent risk factor for general
morbidity after cardiac surgery (Fowler et al.) and the
scale of this impact on total morbidity burden (TMB)
has yet to be reported.
Thus, we explored the association between pre-
operative anaemia and RBC transfusion requirement with
TMB after cardiac surgery.
Methods
Participants
Patients were drawn from the Cardiac Post-Operative
Morbidity Score (C-POMS) development and validation
study; the methods describing how the C-POMS meas-
urement tool was developed and validated are detailed
elsewhere (Sanders et al.). In brief, patients undergoing
any form of adult cardiac surgery (excluding cardiac
surgery for a congenital heart condition or a cardiomy-
opathy) between January 2005 and November 2007 at
the Heart Hospital, University College London Hospitals
NHS Trust, UK, and who gave written informed consent
were eligible for inclusion. Excluded were those <18 years
old, undergoing emergency surgery, who were enrolled
in clinical intervention trials or who died within 5 days
of surgery.
Defining anaemia
Anaemia was defined as a haemoglobin (Hb) concen-
tration below 130 g/l for men and 120g/l for women
(Organisation WH 2008).
Outcome measurements
Post-operative morbidity and hence total morbidity
burden were defined using the C-POMS tool (Table 1).
RBC transfusion
Allogenic RBC transfusions were defined as any RBC
transfusion given to the participant in the intra- and
post-operative period prior to discharge from hos-
pital and were collected by staff using the C-POMS
tool (Table 1).
At the time of data collection, there was no uniform
protocol for blood transfusion, although the unit oper-
ated a generally restrictive transfusion policy. Trust
guidelines stipulated that RBC transfusion was strongly
indicated when the haemoglobin was below 70 g/l. Since
November 1999, all allogeneic blood components pro-
duced in the UK have been subjected to leucocyte de-
pletion (LD) whereby ≥99% of units have <5 × 106
leucocytes and >90% <1 × 106 leucocytes (Service UKBT
and T 2007).
Total morbidity burden: C-POMS summary score
Post-operative morbidity was prospectively assessed on
days 3 (D3), 5 (D5), 8 (D8) and 15 (D15) after cardiac
surgery using the C-POMS tool (Sanders et al.). This
represents TMB as a summary score (0–13), derived by
noting the new or escalating presence or absence of 13
morbidity domains. Thus, the higher the score, the more
morbidity experienced by the patient (Table 1).
Post-operative length of stay
Post-operative length of stay (LOS) was defined as the
number of days from surgery (day of operation day 0) to
discharge from hospital. This included any days spent in
a receiving hospital following transfer from the operative
hospital.
Other clinical data
Other clinical information including patient demo-
graphic details, relevant medical history, symptoms, risk
factors, intra-operative details and general outcome
variables (as shown in Table 2) were extracted from the
C-POMS study. These were originally obtained from
the medical and nursing records and the Society of
Cardiothoracic Surgery of Great Britain and Ireland’s
local database.
Statistical analysis
All statistical analyses were performed in Stata version
13 (StataCorp Texas).
Baseline characteristics by anaemia were compared
using Fisher’s exact test for categorical variables and
Mann-Whitney U test for continuous data. The associ-
ation of transfusion with anaemia after adjustment for
covariates (age, gender and EuroSCORE) was assessed
using a logistic regression model, and the odds ratio and
95% confidence interval were obtained. Associations
with individual C-POMS morbidities were examined
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using random intercept logistic regression models. p values
were corrected for multiple comparisons over the 13
morbidities using the Bonferroni correction.
Hb concentration at each time point was divided into
quintiles, and differences in C-POMS score were tested
between quintiles using Kruskal-Wallis test and a non-
parametric test for trend across ordered groups (Cuzick
1985). Differences in C-POMS by quintile over all time
points were estimated using a random intercept model
with time fitted as a fixed effect.
Correlations of Hb with LOS and C-POMS score were
assessed by Spearman rank correlation, and multivariate
Table 1 The Cardiac Post-Operative Morbidity Score (C-POMS) (Sanders et al.)
Morbidity type C-POMS criteria
Pulmonary Presence of one or more of the following:
■ New requirement for oxygen or respiratory support (including nebuliser therapy or request for
chest physiotherapy on or after D5)
■ Pleural effusion requiring drainage
Infectious Presence of one or more of the following:
■ Currently on antibiotics
■ A temperature of >38 °C in the last 24 h
■ A white cell count/CRP level requiring in-hospital review or treatment
Renal Presence of one or more of the following:
■ Decreased urine output requiring intervention (including IV furosemide)
■ Increased serum creatinine (>30% from pre-operative level)
■ Urinary catheter in situ
■ New urinary incontinence
■ Serum potassium abnormalities requiring treatment
Gastrointestinal Presence of one or more of the following:
■ Unable to tolerate an enteral diet for any reason including nausea, vomiting and abdominal distension
■ The presence of a nasogastric tube
■ Diagnosis of a gastrointestinal bleed
■ Diarrhoea
Cardiovascular Presence of one or more of the following:
■ The use of inotropic therapy for any cardiovascular cause
■ Pacing wires (on or after D5) and/or requiring temporary or new permanent pacing
■ Diagnostic tests or therapy within the last 24 h for any of the following: (1) new MI or ischaemia,
(2) hypotension (requiring fluid therapy, pharmacological therapy or omission of pharmacological
therapy), (3) atrial or ventricular arrhythmias, (4) cardiogenic pulmonary oedema, thrombotic event
(requiring anticoagulation), (5) hypertension (pharmacological therapy or omission of pharmacological therapy)
Neurological New neurological deficit (including confusion, delirium, coma, lack of coordination, drowsy/slow to wake,
poor swallow, blurred vision, sedated, changing loss of consciousness)
Haematological Presence of one or more of the following:
■ Untherapeutic INR requiring pharmacological therapy or omission of pharmacological therapy
■ Requirement for any of the following within the last 24 h: packed erythrocytes, platelets, fresh-frozen
plasma or cryoprecipitate
Wound Presence of one or more of the following:
■ Wound dehiscence requiring surgical exploration or drainage of pus from the operation wound with
or without isolation of organisms
■ Chest drains
■ Wound pain significant enough to require continuing or escalating analgesic intervention
Pain Post-operative pain significant enough to require parenteral opioids and/or continuing or additional analgesia.
Endocrine New or additional requirements for blood sugar management
Electrolyte Electrolyte (including sodium, urea, phosphate) imbalance requiring oral or intravenous intervention
(not including potassium as included in renal category)
Review Remaining in hospital for further review, investigation and/or procedure
Assisted ambulation A new or escalated post-operative requirement for mobility assistance (including wheelchair, crutches,
zimmer frame, walking sticks or assistance)
Non-C-POMS related reasons for delayed discharge on D5, D8 and D15 which the PDG decided should also be routine data collection in
C-POMS on these days.
Non-morbidity reason
for delayed discharge
Where C-POMS is ‘0’ but the patient remains in hospital, state the reason for lack of discharge:
Social reasons; Equipment at home; Mobility (ongoing physic and OT needs); Institutional failure (transport
not booked, OPA or follow-up not arranged); Delayed discharge (lack of rehab or other bed); Discharge
planned for today; Other medical reason
CRP C-reactive protein, IV intravenous, MI myocardial infarction, INR international normalised ratio, OPA out-patient appointment, OT occupational therapy
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Table 2 Baseline characteristics (n = 442, unless otherwise stated). All values n(%) unless otherwise stated
Overall Anaemic Not anaemic P (anaemic
vs not anaemic)(n = 442) (n = 139) (n = 303)
Frequency (%)/mean ± SD Frequency (%)/mean ± SD Frequency (%)/mean ± SD
Demographics
Age (mean/years) 66.5 ± 10.6 69.5 ± 10.5 65.11 ± 10.4 0.000
Female gender 92 (20.8) 32 (23.0) 60 (19.8) 0.451
Ethnicity (White British) (n = 438) 377 (86.1) 106 (76.8) 271 (90.3) 0.001
Medical history
Renal (dialysis) 7 (1.6) 6 (4.3) 1 (0.3) 0.005
History of previous MI (n = 415) 147 (35.4) 49 (38.0) 98 (34.3) 0.375
Re-operation 18 (4.1) 8 (5.8) 10 (3.3) 0.299
Cerebrovascular accident 16 (3.6) 9 (6.5) 7 (2.3) 0.050
Gastrointestinal disease 50 (11.3) 23 (16.5) 2 (8.9) 0.023
Congestive heart failure (n = 415) 13 (3.1) 8 (6.2) 5 (1.7) 0.034
Symptoms
NYHA class (n = 441)
- I 114 (25.9) 32 (23.0) 82 (27.2) 0.245
- II 204 (46.3) 65 (46.8) 139 (46.0)
- III 101 (22.9) 31 (22.3) 70 (23.2)
- IV 22 (5.0) 11 (2.5) 11 (3.6)
Cardiac risk factors
Smoking
- Current 49 (11.1) 14 (10.1) 35 (11.6) 0.891
- Ex 244 (55.2) 77 (55.4) 167 (55.1)
- Never 149 (33.7) 48 (34.5) 101 (33.3)
Hypertension 302 (68.3) 95 (68.3) 207 (68.3) 1.000
Hypercholesteraemia 341 (77.1) 101 (72.7) 240 (79.5) 0.142
Diabetes 103 (23.3) 53 (38.1) 50 (16.5) 0.000
BMI (kg/m2)/mean 28.6 ± 5.7 28.1 ± 6.0 28.8 ± 5.5 0.262
Examination and investigation
LVEF (n = 434)
- Good 323 (74.4) 101 (74.3) 222 (74.5) 0.167
- Fair 88 (20.3) 24 (17.6) 64 (21.5)
- Poor 23 (5.3) 11 (8.1) 12 (4.0)
Number diseased vessels (n = 435)
- 0 79 (18.2) 28 (20.6) 51 (17.1) 0.799
- 1 34 (7.8) 10 (7.4) 24 (8.0)
- 2 80 (18.4) 26 (19.1) 54 (18.1)
- 3 242 (55.6) 72 (52.9) 170 (56.9)
Pre-operative risk assessment
EuroSCORE (median [IQR]) 4 [1–5] 5 [2–6] 3 [1–4] 0.000
Intra-operative details
Operative priority
-Elective 308 (69.7) 73 (52.5) 235 (77.6) 0.000
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models were fitted for patient LOS and C-POMS score
using ordinal logistic regression and random intercept
models, respectively. Terms for both EuroSCORE and
Hb were fitted as quintiles in the multivariate models as
their distributions differed significantly from normality.
Results
Baseline characteristics
Of 748 potentially eligible patients undergoing cardiac
surgery, 520 (69.5%) were screened (due to researcher avail-
ability) and 464 (89.2%) consented to participate. Fourteen
participants subsequently became ineligible, leaving 450
who completed the study. Six participants declined for their
data to be used outside the development of C-POMS, and
a further two patients were without pre-operative Hb
results, leaving 442 patients for analysis in this study.
Table 2 summarises the participants’ characteristics.
Overall, the majority were White British (377, 86.1%) and
male (350, 79.2%) with a mean age of 66.5 years (range 19
to 91 years). Seven patients (1.6%) were receiving renal
dialysis while 50 (11.3%) had gastrointestinal disease. Most
underwent isolated coronary artery bypass graft (CABG)
surgery (298, 67.4%) and received cardiopulmonary bypass
(410, 93.4%). Overall, the patients remained in the ICU
and hospital for 2.0 and 11.8 days, respectively.
Pre-operative anaemia
The overall median Hb was 135 (range 79 to 173). Pre-
operative anaemia was present in 31.5% (139/442)
participants. The median Hb in the anaemic group was
116 (range 79 to 129 g/l) and 140 (range 120 to 173 g/l)
in the non-anaemic groups (p = 0.000).
Table 2 shows the comparison of the pre-, intra- and
post-operative characteristics between those with and
without anaemia. Patients with pre-operative anaemia
were older (69.5 vs 65.1 years, p = 0.000), less likely to be
of White British ethnicity (76.8 vs 90.3%, p = 0.001) and
more likely to be receiving pre-operative dialysis (4.3 vs
0.3%, p = 0.005) than non-anaemic participants. Those
with anaemia were also more likely to have a history of
cerebrovascular accident (6.5 vs 2.3%, p = 0.05), ga-
strointestinal (GI) disease (16.5 vs 8.9%, p = 0.023) or
congestive heart failure (CHF) (6.2 vs 1.7%, p = 0.034)
and to be diabetic (38.1 vs 16.5%, p = 0.000). Thus, as
would be expected, anaemic patients had a higher
EuroSCORE (5 vs 3, p = 0.000) and were more likely to
be undergoing urgent (non-elective) surgery (47.5 vs
22.4%, p = 0.000). Furthermore, compared to non-anaemic
patients, those with anaemia were more likely to return to
theatre (9.6 vs 2.7%, p = 0.003), be readmitted to the ICU
(8.4 vs 1.4%, p = 0.001) and so to stay longer in the ICU
(3.0 vs 1.6 days, p = 0.000) and in hospital (15.2 vs
10.2 days, p = 0.000).
Pre-operative anaemia and RBC transfusion
Pre-operative anaemic patients were more likely to
receive a RBC transfusion than non-anaemic patients
(39.6 vs 14.5%, unadjusted odds ratio (OR) (95%CI)
Table 2 Baseline characteristics (n = 442, unless otherwise stated). All values n(%) unless otherwise stated (Continued)
Operation performed
- CABG 298 (67.4) 86 (61.9) 212 (70.0) 0.103
- AVR 61 (13.8) 18 (12.9) 43 (14.2)
- MVR 10 (2.3) 5 (3.6) 5 (1.7)
- CABG + AVR 35 (7.9) 14 (10.1) 21 (6.9)
- CABG +MVR 0 (0.0) 0 (0.0) 0 (0.0)
- AVR + MVR 3 (0.7) 0 (0.0) 3 (1.0)
- CABG + AVR + MVR 2 (0.5) 0 (0.0) 2 (0.7)
- Other 33 (7.5) 16 (11.5) 17 (5.6)
Duration of operation (min) 224.0 ± 54.1 230.3 ± 64.5 221.0 ± 48.3 0.098
Cardiopulmonary bypass used 410 (93.4) 139 (92.8) 281 (93.7) 0.837
Cardiopulmonary bypass time (n = 428) 79.0 ± 35.8 80.8 ± 41.6 78.2 ± 32.8 0.495
Aortic cross clamp time 51.0 ± 24.9 52.7 ± 29.5 50.26 ± 22.6 0.362
Outcome
Number of hours ventilated (h) (n = 392) 9.84 ± 58.2 8.0 ± 6.6 10.6 ± 69.3 0.690
Length of ICU stay (mean/days) (n = 416) 2.0 ± 3.5 3.0 ± 5.7 1.6 ± 1.6 0.000
Readmitted to ICU 15 (3.4) 11 (8.4) 4 (1.4) 0.001
Return to theatre 21 (4.8) 13 (9.6) 8 (2.7) 0.003
Total length of hospital stay (mean/days) 11.8 ± 11.7 15.2 ± 17.2 10.2 ± 7.6 0.000
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3.85 (2.42–6.15) p < 0.0001) and, if transfused, to re-
ceive more units (2 vs 1 unit, p = 0.04). The associ-
ation between anaemia and transfusion remained after
adjustment for age, gender, EuroSCORE and LOS.
Overall, anaemic patients had over three times the
odds (OR 3.08, 95%CI 1.88–5.06, p < 0.001) of requir-
ing a RBC transfusion than non-anaemic patients
(14.1 vs 33.6%).
Patients who received a RBC transfusion remained
in hospital 5 days longer than those who did not
(LOS 11 vs 6 days, p < 0.0001) and had a significantly
higher C-POMS score on all days (D3 5 vs 3, D5 3
vs 2, D8 4 vs 3, D15 4 vs 2, all p < 0.001) (Fig. 1).
Furthermore, RBC transfusion was associated with
pulmonary, renal, GI, neurological, endocrine and am-
bulation morbidities (p 0.026 to <0.001), independent
of Hb (Table 3).
Pre-operative anaemia and C-POMS score
Pre-operative Hb was correlated with C-POMS score on
D3 (rho −0.28, p < 0.0001) and D5 (rho −0.18, p = 0.0002)
but not D8 (rho −0.143, p = 0.06) or D15 (rho −0.28,
p = 0.06). Patients with pre-operative anaemia had a
significantly higher C-POMS score on D3 and D5
than non-anaemic patients (5 vs 3 and 3 vs 2, respectively,
both p < 0.0001) but not on D8 (3 vs 3, p = 0.32) or D15
(3.5 vs 3, p = 0.27) (Fig. 2). Pre-operative anaemia was
associated with renal (p < 0.001) and assisted ambulation
(p = 0.003) but no other C-POMS domains (Table 4).
Both pre-operative anaemia and transfusion re-
quirement were independently associated with an
increased C-POMS score (Table 5). Pre-operative an-
aemia was associated with a 0.55 (se 0.20) p = 0.005
increase in score, while RBC transfusion requirement
was associated with an increase score of 1.23 (se
0.22) (p < 0.0001). If Hb replaced anaemia in this
statistical model, both Hb and transfusion are inde-
pendently associated with C-POMS score. C-POMS
score decreases with every one quintile increase in
Hb (B (se) −0.18 (0.06) p = 0.003) and increases by
1.19 with transfusion (se 0.22) (p < 0.0001). Increased
age was also independently associated with increased
C-POMS score in both models.
Pre-operative anaemia and hospital LOS
Pre-operative Hb was correlated with hospital LOS
(rho −0.32, p < 0.00001). When compared to patients
with Hb >14.6 (quintile 5), those with Hb <12.1
(quintile 1) had a higher morbidity score on D3 (5 vs
2, p < 0.0001) and D5 (3 vs 2, p = 0.007) and stayed in
hospital for an additional 4 days (LOS 10 vs 6 days,
p < 0.001) (Table 6). Pre-operative anaemic patients
Fig. 1 C-POMS summary score by red blood cell transfusion
Table 3 Morbidity outcome by domain following RBC transfusion
C-POMS morbidity domain OR (95%CI)a p value Bonferroni adjusted p value
Pulmonary 3.55 (1.87–6.73) 0.0001 0.001
Infectious 1.71 (0.71–4.15) 0.232 1.00
Renal 4.52 (1.88–10.83) 0.001 0.013
Gastrointestinal 2.58 (1.42–4.68) 0.002 0.026
Cardiovascular 4.14 (1.37–12.47) 0.012 0.156
Neurological 5.89 (2.65–13.09) 0.00001 0.0001
Haematological 2.98 (1.20–7.41) 0.019 0.247
Wound 1.89 (0.66–5.40) 0.237 1.000
Pain 1.39 (0.51–3.78) 0.514 1.000
Endocrine 4.40 (1.97–9.84) 0.0003 0.004
Electrolyte 0.66 (0.14–3.08) 0.594 1.000
Review 1.97 (1.06–3.64) 0.032 0.416
Assisted ambulation 6.49 (2.57–16.40) 0.00008 0.001
aOdds ratio for association of transfusion with domain after adjustment for age, gender, time point and Hb
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remained in hospital 2 days longer than non-anaemic
patients (8 (inter-quartile range (IQR) 6–15) vs 6
(IQR 5–9) days, p < 0.0001, respectively).
Both pre-operative anaemia (OR 1.65, 95%CI 1.12–2.44,
p = 0.01) and RBC transfusion requirement (OR 2.40,
95%CI 1.55–3.72, p < 0.001) were independently associ-
ated with increased hospital LOS (Table 7). If Hb level
replaces pre-operative anaemia in the analysis model,
there is a linear decrease in LOS over the five quintiles
with odds ratios vs quintile 1 of 0.78, 0.64, 0.49 and 0.42
for quintiles 2 to 5. Lower Hb (OR per quintile of Hb 0.80,
95%CI 0.70–0.92, p = 0.001) and RBC transfusion require-
ment (OR 2.33, 95%CI 1.50–3.60, p = 0.0002) were inde-
pendently associated with increased hospital LOS.
Discussion
Pre-operative anaemia has been associated with adverse
outcome after cardiac surgery. However, whether anaemia
is an independent risk factor for general morbidity after
cardiac surgery (Fowler et al.) and the scale of this impact
on total morbidity burden (TMB) has not previously been
reported. Thus, our study explored the effect of pre-
operative anaemia and RBC transfusion on total morbidity
burden after cardiac surgery. Firstly, we found that com-
pared to non-anaemic patients, pre-operative anaemic
patients had significantly higher TMB (C-POMS scores)
on D3 and D5, significantly more renal and ambulation
morbidities and stayed in ICU and hospital an extra
1.4 days and an extra 2 days, respectively. As pre-
operative anaemia was independently associated with in-
creased TMB, reduction of post-operative morbidity
might be achieved by treating pre-operative anaemia. In-
deed, pre-operative optimization of anaemia in the UK is
recommended (Service UKBT and T 2007; Department of
Health 2007) as part of the patient blood management
plan, with the use of intravenous (IV) iron if surgery may
be delayed due to the time needed for oral iron to take ef-
fect (ERP Programme 2010). However, although IV iron
therapy for anaemia has been shown to effectively treat
anaemia in medical (Usmanov et al. 2008), and non-
cardiac pre-operative settings (Munoz et al. 2009), the
effect on cardiac surgical patients is not yet confirmed due
to the low level of evidence available (Hogan et al. 2015).
Thus, further prospective evidence in cardiac surgery pa-
tients is required before any recommendation for the use
of IV iron to treat pre-operative anaemia in these patients
can be made. Secondly, blood is a limited resource and is
associated with high transfusion costs (Department of
Health 2007), administration incidents and risks (Group
SS 2014) and specifically poorer outcome in cardiac surgi-
cal patients (Galas et al. 2013). Our results found RBC
transfusion to be independently associated with TMB, and
patients spent an extra 5 days in hospital. Thus, strategies
Fig. 2 C-POMS summary score by pre-operative anaemia
Table 4 Pre-operative anaemia and morbidity outcome by domain
C-POMS morbidity domain OR (95%CI)a p value Bonferroni adjusted p value
Pulmonary 1.60 (0.93–2.76) 0.088 1.00
Infectious 1.87 (0.84–4.17) 0.125 1.00
Renal 6.88 (2.97–15.92) 0.000006 0.00008
Gastrointestinal 0.89 (0.52–1.53) 0.674 1.000
Cardiovascular 1.64 (0.62–4.31) 0.319 1.000
Neurological 0.81 (0.40–1.66) 0.571 1.000
Haematological 1.35 (0.60–3.03) 0.467 1.000
Wound 2.12 (0.80–5.62) 0.133 1.000
Pain 1.53 (0.63–3.75) 0.349 1.000
Endocrine 2.83 (1.38–5.80) 0.005 0.065
Electrolyte 2.73 (0.70–10.68) 0.150 1.000
Review 1.22 (0.68–2.20) 0.510 1.000
Assisted ambulation 4.96 (2.16–11.38) 0.0002 0.0026
aOdds ratio for association of anaemia with domain after adjustment for age, gender, time point and transfusion
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to reduce RBC use may reduce transfusion errors, re-
duce healthcare costs and improve patient well-being.
However, although there are considerable differences
in transfusion triggers across UK cardiac surgery cen-
tres (Murphy et al. 2013), restrictive transfusion protocols
(Ternström et al. 2014) and patient blood management
systems (Gross et al. 2015) do not appear to reduce post-
operative morbidity in all instances, with the TITRe2 trial
suggesting liberal transfusion may actually be superior
after cardiac surgery (Murphy et al. 2015). This again
raises the question on whether it is anaemia or RBC trans-
fusion that carries the greatest risk (Vincent 2015; Du
Pont-Thibodeau et al. 2014), and hence, exploring TMB in
future anaemia and transfusion studies in cardiac surgery
is needed. Adding further complexity to our understand-
ing of pre-operative anaemia, treatment strategies and
outcome, hepcidin, the principal regulator of systemic iron
homeostasis, has been found to be an independent risk
factor for poor outcome (Hung et al. 2015). This provides
a new variable for consideration in further work, which is
much needed before any conclusions can be made.
Where evidence exists, our study is comparable to
other studies in terms of incidence of anaemia (De Santo
et al. 2009; Kulier et al. 2007) and medical history (De
Santo et al. 2009; Kulier et al. 2007). Our results were
also consistent with others identifying pre-operative
anaemia as a risk factor for post-operative renal compli-
cations (Cladellas et al.; Miceli et al. 2014; Fowler et al.)
but not for cardiovascular complications (Cladellas et al.;
Miceli et al. 2014; Fowler et al.; Carrascal et al. 2010).
However, our findings did not suggest pre-operative an-
aemia to be associated with stroke (Miceli et al. 2014;
Fowler et al.), infection (Cladellas et al.; Fowler et al.) or
respiratory failure (Carrascal et al. 2010) as has been
found previously. This is likely to be due to difference in
definitions used between the studies, and thus the use of a
standardised framework, like C-POMS, is advocated for
future morbidity outcome after cardiac surgery studies.
There are four main limitations with our study. Firstly,
pre-operative baseline characteristics obtained from the
Society of Cardiothoracic Surgery of Great Britain and
Ireland local database were 93.9% complete. It is possible
the small amount of missing data may have had an influ-
ence on comparisons on the baseline characteristics.
Secondly, although C-POMS is a validated tool for the
description and quantification of morbidity after cardiac
surgery (Sanders et al.), there are limitations to its use
(Sanders et al.). This includes transient morbidities
which may be missed on non-data collection days and
that fluctuations cannot be tracked. Thirdly, as it is
recommended that treatment of pre-operative anaemia
should rely on the diagnosis of the type of anaemia,
identifying the underlying cause or disease (Weiss and
Goodnough 2005), we had intended to explore outcome
by type of anaemia. However, since only 1.4% (2/139) of
anaemic patients in our study had pre-operative
Table 5 Multivariate models for associations with C-POMS
Model including anaemia Model including Hb
B (se) p value B (se) p value
Age 10-year increase −0.15 (0.10) 0.13 −0.16 (0.10) 0.11
Gender Female/male −0.15 (0.22) 0.49 −0.34 (0.23) 0.13
EuroSCORE Per quintile 0.48 (0.08) <0.0001 0.48 (0.08) <0.0001
Anaemia Yes/no 0.55 (0.20) 0.005 – –
Hb 1 SD increase – – −0.29 (0.10) 0.003
Transfusion Yes/no 1.23 (0.22) <0.0001 1.19 (0.22) <0.0001
Table 6 Median C-POMS score and hospital length of stay by quintile of Hb
Quintile D3 D5 D8 D15 All time points Hospital LOS
Median [IQR] Median [IQR] Median [IQR] Median [IQR] Ba (se) Median [IQR]
1 (≤121) 5 [2–6] 90 3 [1–5] 87 4 [2–6] 54 4 [2–7.5] 20 0 10 [6–17.5] 88
2 (122–131) 4 [2–5] 93 2 [1–4] 90 3 [2–4] 43 3 [2–3] 7 −0.82 (0.29) 7.5 [6–11] 90
3 (132–138) 2 [1–5] 82 2 [1–3] 80 3 [1–4] 31 2 [2–6] 7 −1.34 (0.30) 6.5 [5–10] 82
4 (139–146) 3 [1–5] 89 2 [1–3] 82 3 [2–5] 29 3 [1–4] 6 −1.25 (0.29) 6 [5–9] 88
5 (>146) 2 [1–4] 85 2 [1–3] 78 3 [1–4] 19 2.5 [1.5–3] 4 −1.71 (0.29) 6 [5–8] 86
p value <0.0001 0.007 0.28 0.67 <0.0001 <0.0001
p value (trend) <0.0001 0.001 0.16 0.15 <0.0001 <0.0001
IQR inter-quartile range
aDifference in C-POMS score for each quintile compared to quintile 1 after adjustment for day of follow-up
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haematinic profiles available, this was not feasible.
Finally, we cannot prove that the associations we report
are causal. Investigating this issue will require interven-
tional studies to mitigate against pre-operative anaemia
and post-operative transfusion, and we would advocate
for such trials to take place.
Conclusions
In conclusion, while previous evidence is inconclusive
on the effect of pre-operative anaemia-specific morbidity
outcome (for example stroke and renal dysfunction)
after cardiac surgery, our study suggests that pre-
operative anaemia and RBC transfusion use are inde-
pendently associated with significant overall total mor-
bidity burden following cardiac surgery. Thus, strategies
to reduce pre-operative anaemia and RBC transfusion
need are important. However, understanding that TMB
(at the level of detail that the C-POMS tool permits) as-
sociated with pre-operative anaemia and RBC transfu-
sion may assist in post-operative patient management to
reduce morbidity, especially if it is not possible to ascer-
tain whether it is anaemia or RBC transfusion that car-
ries the greatest risk to patient well-being and recovery.
We would recommend the use of the C-POMS tool as a
standard morbidity outcome measurement tool in fur-
ther studies to explore this and whether interventions
implemented to reduce post-operative morbidity burden
actually do reduce TMB as measured using the C-POMS
tool.
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